Closely held Specific Biologics has announced the closing of an oversubscribed $35 million Series A financing. The round was led by Hatteras Venture Partners, with participation from foundational investors Lumira...
HeartBeam (NASDAQ: BEAT) has revealed positive results today from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment presented by Graham Nichol, MD, MPH, FRCP(C), of the University of...
NeuroSense Therapeutics (NASDAQ: NRSN) has announced plans to incorporate newly generated data into its New Drug Submission (NDS) to Health Canada for PrimeC, its lead investigational therapy for amyotrophic lateral...
Allarity Therapeutics (NASDAQ: ALLR) has announced its first revenue-generating contract under its newly established Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory services strategy, which is...
Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has entered into a supply and distribution agreement with the iMRI Division of closely held Cook Medical to expand U.S. sales of its TULSA-PRO system...
Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT has received a special mention in TIME’s Best Inventions of 2026, earning national recognition for its approach to helping surgeons identify...
Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI) will evaluate the therapeutic efficacy of Entolimod in a post-radiation treatment model designed to assess whether...
An October 28, 2026 fire at a South Carolina complex that once produced plutonium and tritium for nuclear weapons is a timely reminder of the importance of resilient emergency preparedness for potential radiological and...
Celularity (NASDAQ: CELU) and Vesalius Longevity Labs (CSE: VLAB) have announced an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform...
Azitra (NYSE American: AZTR) has announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that significantly expand patient eligibility to include individuals with rash associated with KRAS and MEK...
Valion Bio (NASDAQ: VBIO) has announced final data from a safety study funded by the National Institute of Allergy and Infectious Diseases (NIAID)/Radiation and Nuclear Countermeasures Program (RNCP) that evaluated its...
FireFly Neuroscience (NASDAQ: AIFF) has provided an update on its non-invasive brain-computer interface (BCI) strategy, highlighting the role of its commercially available Versus platform in pursuing the human...
Clearmind Medicine (NASDAQ: CMND) announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase 1/2a clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol...
IRLAB Therapeutics (STO: IRLAB-A; FRA: 6IRA) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering IRL1117, a preclinical drug candidate...
Atrium Therapeutics (NASDAQ: RNA) has announced that the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2...
Aclaris Therapeutics (NASDAQ: ACRS) has announced positive primary analysis results from the Phase 1b proof-of-concept (POC) trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma...
Closely held Dragonfleye Therapeutics has announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of $37.5 million. Participants included healthcare...
TuHURA Biosciences (NASDAQ: HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell Carcinoma...
MacroGenics (NASDAQ: MGNX) has announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, in patients with advanced clear cell...
Pasithea Therapeutics (NASDAQ: KTTA) has announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated population of...
Zentalis Pharmaceuticals (NASDAQ: ZNTL) presented results today from an interim analysis of the DENALI Part 1b study as of a May 22, 2026, data cutoff, including the first overall survival (OS) analysis for azenosertib...
Profound Medical (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let’s Huddle...